ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2013
Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Are the Conventional Commercial Yeast Identification Methods Still Helpful in the Era of New Clinical Microbiology Diagnostics? A Meta-Analysis of Their Accuracy.Journal of clinical microbiology · 2015Pooled it
- The Antimicrobial Resistance ofJournal of fungi (Basel, Switzerland) · 2025Article
- Iron modulation drives biofilm formation and virulence enzyme production in emerging clinicalFrontiers in fungal biology · 2025Article
- Fungal coinfection/superinfection in COVID-19 patients in a tertiary hospital in MexicoBiomedica : revista del Instituto Nacional de Salud · 2024Article
- First report of amphotericin B resistantIranian journal of microbiology · 2024Article
- EnhancedCurrent medical mycology · 2023Article
- A study of the association between virulence factors and antifungal susceptibility profile ofJournal of family medicine and primary care · 2023Article
- High Prevalence ofVeterinary sciences · 2022Article
- Advanced approach for antifungal susceptibility and characterization of resistance properties in clinical and environmental isolates ofInfectious medicine · 2022Article
- Metagenomic Assessment of the Pathogenic Risk of Microorganisms in Sputum of Postoperative Patients With Pulmonary Infection.Frontiers in cellular and infection microbiology · 2022Article
- Virulence Factors and Antifungal Susceptibility Profile ofJournal of fungi (Basel, Switzerland) · 2021Article
- Prevalence and Antifungal Susceptibility Profile of Clinically RelevantBioMed research international · 2020Article
- [Identification and susceptibility profile ofRevista panamericana de salud publica = Pan American journal of public health · 2020Article
- The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2019Article
- Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern.BMC women's health · 2018Article
- SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY.Revista do Instituto de Medicina Tropical de Sao Paulo · 2015Review
- Identification and Antifungal Susceptibility Testing ofJournal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eleven quality control isolates (Candida albicans ATCC 64548, C. tropicalis ATCC 200956, C. glabrata ATCC 90030, C. lusitaniae ATCC 200951, C. parapsilosis ATCC 22019, C. krusei ATCC 6258, C. dubliniensis ATCC 6330, Saccharomyces cerevisiae ATCC 9763, Cryptococcus neoformans ATCC 90012, C. gattii FIOCRUZ-CPF 60, and Trichosporon mucoides ATCC 204094) and 32 bloodstream isolates, including C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei, C. guilliermondii, C. pelliculosa (Pichia anomala), C. haemulonii, C. lusitaniae, and C. kefyr were identified at the species level by the VITEK 2 system. A set of clinical isolates (32 total) were used as challenge strains to evaluate the ability of the VITEK 2 system to determine the antifungal susceptibility of yeasts compared with the CLSI and EUCAST BMD reference standards. The VITEK 2 system correctly identified 100% of the challenge strains. The identification of yeast species and the evaluation of their susceptibility profiles were performed in an automated manner by the VITEK 2 system after approximately 15 h of growth for most species of Candida. The VITEK 2 system ensures that each test is performed in a standardized manner and provides quantitative MIC results that are reproducible and accurate when compared with the BMD reference methods. This system was able to determine the MICs of amphotericin B, flucytosine, voriconazole, and fluconazole in 15 h or less for the most common clinically relevant Candida species. In addition, the VITEK 2 system could reliably identify resistance to flucytosine, voriconazole, and fluconazole and exhibits excellent quantitative and qualitative agreement with the CLSI or EUCAST broth microdilution reference methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.